0WA2 Stock Chart & Stats
€2.52
€0.05(1.95%)
At close: 4:00 PM EDT
€2.52
€0.05(1.95%)
Day’s Range― - ―
52-Week Range€1.10 - €4.84
Previous CloseN/A
Volume283.00
Average Volume (3M)2.40K
Market Cap
€100.60M
Enterprise Value€205.35
Total Cash (Recent Filing)€166.85M
Total Debt (Recent Filing)€84.57M
Price to Earnings (P/E)―
Beta0.36
Next Earnings
Nov 09, 2026EPS Estimate
-0.16Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.65
Shares Outstanding72,325,455
10 Day Avg. Volume3,983
30 Day Avg. Volume2,396
Financial Highlights & Ratios
PEG Ratio-0.10
Price to Book (P/B)6.52
Price to Sales (P/S)6.52
P/FCF Ratio-11.22
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.7
Revenue Forecast (FY)€45.39M
Bulls Say, Bears Say
Bulls Say
Gene-edited Allogeneic Therapy PlatformThe company’s focus on gene editing and allogeneic, off-the-shelf cell therapies addresses a potentially more scalable model than individualized treatments. Its capabilities in cell engineering and investigational product design provide a platform for multiple oncology programs.
Strong Gross-margin ProfileA gross margin near 75% indicates that the underlying technology and collaboration-related activities can generate substantial value after direct costs. If revenue expands through partnerships or successful programs, this margin profile could support better operating leverage over time.
Multiple Partnership Monetization AvenuesCellectis can monetize its platform through several partner-linked payment types rather than relying only on future product sales. Upfront fees, milestones, services, licenses, and potential royalties create multiple routes to fund development and capture value from successful programs.
Bears Say
Declining RevenueFalling and volatile revenue makes it harder to establish a predictable funding base for clinical development. This weakens visibility into the pace of scaling and increases reliance on new collaborations, milestones, or other financing while product candidates remain in development.
Deep Operating LossesThe scale of ongoing operating losses shows that current revenue does not support the company’s cost structure. Persistent losses can consume capital needed for clinical programs and delay the point at which successful development efforts translate into sustainable operating profitability.
Cash Burn And Weaker Equity CushionSizable operating and free-cash-flow deficits indicate continuing funding needs, while higher debt relative to a reduced equity base leaves less balance-sheet protection. This combination can constrain development investment and reduce flexibility if losses persist or capital needs increase.
Cellectis SA News
0WA2 FAQ
What was Cellectis SA’s price range in the past 12 months?
Cellectis SA lowest share price was €1.10 and its highest was €4.84 in the past 12 months.
What is Cellectis SA’s market cap?
Cellectis SA’s market cap is €100.60M.
When is Cellectis SA’s upcoming earnings report date?
Cellectis SA’s upcoming earnings report date is Nov 09, 2026 which is in 45 days.
How were Cellectis SA’s earnings last quarter?
Cellectis SA released its earnings results on Aug 06, 2026. The company reported -€0.19 earnings per share for the quarter, beating the consensus estimate of -€0.227 by €0.037.
Is Cellectis SA overvalued?
According to Wall Street analysts Cellectis SA’s price is currently Overvalued.
Does Cellectis SA pay dividends?
Cellectis SA does not currently pay dividends.
What is Cellectis SA’s EPS estimate?
Cellectis SA’s EPS estimate is -0.16.
How many shares outstanding does Cellectis SA have?
Cellectis SA has 72,325,455 shares outstanding.
What happened to Cellectis SA’s price movement after its last earnings report?
Cellectis SA reported an EPS of -€0.19 in its last earnings report, beating expectations of -€0.227. Following the earnings report the stock price went down -1.703%.
Which hedge fund is a major shareholder of Cellectis SA?
Currently, no hedge funds are holding shares in GB:0WA2
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Cellectis SA
Cellectis S.A., a clinical-stage biotechnology company founded in 1999 and headquartered in Paris, France, concentrates on immuno-oncology. The firm engineers therapeutic solutions utilizing gene-edited T-cells, which are modified to display chimeric antigen receptors (CARs) for the specific identification and destruction of cancer cells. Its operations are divided into two principal segments: Therapeutics and Plants. The company's pipeline features several allogeneic CAR T-cell product candidates. These include UCART19, aimed at CD19-expressing hematologic malignancies such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A, developed to treat relapsed or refractory diffuse large B-cell lymphoma and follicular lymphoma; ALLO-316, targeting renal cell carcinoma; UCART123, for acute myeloid leukemia; and UCART22, addressing B-cell acute lymphoblastic leukemia. Additionally, Cellectis is advancing UCARTCS1 and ALLO-715 for the treatment of multiple myeloma. Cellectis has forged significant strategic partnerships and alliances with companies including Allogene Therapeutics, Inc., Les Laboratoires Servier, The University of Texas M.D. Anderson Cancer Center, and Iovance Biotherapeutics. It also maintains a strategic research and development collaboration with Cytovia Therapeutics, Inc.
Technical Analysis
Innate Pharma SA
―
Nanobiotix
―
Transgene
―
OSE Immunotherapeutics SA
―
MaaT Pharma
―